CG620953

CG620953 is a preclinical small molecule dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1). It is being developed by Cullgen, a subsidiary of GNI Group, in collaboration with GNI-EPS Pharmaceuticals for the treatment of various inflammatory diseases. By targeting both TYK2 and JAK1, the compound aims to modulate multiple cytokine signaling pathways involved in autoimmune and inflammatory responses, including those mediated by Type I interferons, IL-12, IL-23, and IL-6. This dual mechanism of action is intended to provide a broader therapeutic profile than selective inhibitors while maintaining a favorable safety profile. The drug is currently in the preclinical stage of development.